A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle | Zendy

O'Neill Paul M. | Zendy; Ward Stephen A. | Zendy

Premium

A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle

Author(s) -

O'Neill Paul M.,

Ward Stephen A.

Publication year - 2015

Publication title -

angewandte chemie international edition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.831

H-Index - 550

eISSN - 1521-3773

pISSN - 1433-7851

DOI - 10.1002/anie.201507264

Subject(s) - malaria , parasite hosting , drug discovery , plasmodium (life cycle) , drug , pharmacology , chloroquine , quinoline , biology , phenotypic screening , computational biology , virology , medicine , immunology , bioinformatics , phenotype , chemistry , genetics , computer science , gene , organic chemistry , world wide web

Putting a stop to malaria : Phenotypic screening against malaria parasites, hit identification, and efficient lead optimization have delivered the preclinical candidate antimalarial DDD107498. This molecule is distinctive in that it has potential for use as a single‐dose cure for malaria and shows a unique broad spectrum of activity against the liver, blood, and mosquito stages of the parasite life cycle.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research